Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura

British Journal of Haematology

Volumn 117, Issue 3, 2002, Pages 712-715

  Howard, Jo ^a,b   Hoffbrand, A Victor ^a   Prentice, H Grant ^a   Mehta, Atul ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Auto immunity; Haemolytic anaemia; Immunosuppression; Mycophenolate mofetil; Thrombocytopenia

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; REFRACTORY ANEMIA; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

EID: 0036098780     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03430.x     Document Type: Article

References (6)

1. Mycophenolate mofetil and its mechanisms of action
2. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for The American Society of Hematology
3. Management of childhood idiopathic thrombocytopenic purpura
4. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection
5. Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine
6. Mycophenolate mofetil for severe autoimmune haemolytic anaemia